VivoSeq
Oncology

Metastasis

135

Pipeline Programs↗

39

Active Trials↗

58

Companies Involved↗

Metastasis is a highly competitive landscape with 135 programs across 58 companies. The most active players are Novita Pharmaceuticals, Inc., Azurity Pharmaceuticals, Pacira Pharmaceuticals, Inc. 23 therapies are approved with 23 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

19/100

Mech. Concentration

3/100

Completion Rate

55/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Novita Pharmaceuticals, Inc.

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc

2 programs

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

2 programs

Phase 2UCB logo

UCB

2 programs

Phase 2J

Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical12

Octreotide Acetate

Novartis

Denosumab

Amgen

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Propofol-Remifentanil

Yonsei University

Gadolinium-Chelate

M.D. Anderson Cancer Center

Phase 121

Dextromethorphan

Pfizer

Axitinib

Prism Pharmaceuticals

Celecoxib

Philadelphia Eye Associates

Hyperpolarized 13c Pyruvate

University of Maryland, Baltimore

Lomustine

Azurity Pharmaceuticals

Phase 256

Atezolizumab

Roche

Encorafenib

Pfizer

Binimetinib

Pfizer

Lenvatinib

Eisai

Regorafenib

Bayer

Phase 323

Peginterferon Alfa-2b

Merck & Co.

Interferon Alfa-2b

Merck & Co.

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Motexafin Gadolinium

Pharmacyclics LLC.

Pemetrexed

Eagle Vision Pharmaceutical Corp.

Approved23

Docetaxel

Avyxa

Abemaciclib

Eli Lilly

Zoledronic Acid

Pfizer

Caffeine

Hikma Pharmaceuticals LLC

Methotrexate

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

87%

Small molecule

132 of 152 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody1611%Radiopharmaceutical21%Cell therapy1<1%Gene therapy1<1%

Small molecule leads; the ring shows all 152 classified programs, each share of the total. Modality classified for 100% of 160 pipeline programs.

Analysis

Trial Status

112

clinical trials

Completed26 · 23%
Unknown status26 · 23%
Recruiting23 · 21%
Terminated12 · 11%
Not yet recruiting8 · 7%
Withdrawn8 · 7%
Other9 · 8%

Clinical Trials

Trial Activity

112 trials

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Recruiting·BBaptist Health South Florida·Phase 1·NCT06048094·46 enrolled
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
Recruiting·FFudan University·Phase 2·NCT05098847·25 enrolled
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
Recruiting·HHenan Cancer Hospital·Phase 2·NCT06945705·146 enrolled
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06462508·30 enrolled
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
Recruiting·HHenan Cancer Hospital·Phase 2·NCT06598046·48 enrolled
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Recruiting·FFudan University·Phase 2·NCT06501391·54 enrolled
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Recruiting·TTang-Du Hospital·N/A·NCT06352502·30 enrolled
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
Recruiting·FFudan University·Phase 2·NCT06501378·40 enrolled
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
Recruiting·JJiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.·Phase 2·NCT07107633·90 enrolled
Colorectal Metastasis Prevention International Trial 2
Recruiting·—·Phase 2·NCT03919461·200 enrolled
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06756334·30 enrolled
Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)
Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT03324360·276 enrolled
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Recruiting·—·N/A·NCT07044362·100 enrolled
A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
Recruiting·—·Phase 3·NCT02102789·142 enrolled
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05404139·132 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)